Interpace Biosciences (IDXG) SC 13D Interpace Diagnostics Group, Inc.

Exhibit 1

Pursuant to Rule 13d-1(k)(1)(iii) of Regulation 13D-G of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended (“Regulation 13D-G”), the undersigned agree that the Schedule 13D to which this Exhibit is attached is, and any additional amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them in the capacities set forth herein below, and that all subsequent amendments to such Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. It is understood and agreed that the joint filing of the Schedule 13D shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G.

Dated: July 25, 2019

Ampersand 2018 Limited Partnership
By: AMP-18 Management Company Limited Partnership, its General Partner
By: AMP-18 MC LLC, its General Partner
By:	/s/ Dana L. Niles
	Name:   Dana L. Niles
	Title:   Chief Operating Officer
AMP-18 Management Company Limited Partnership, its General Partner
By: AMP-18 MC LLC, its General Partner
By:	/s/ Dana L. Niles
	Name:   Dana L. Niles
	Title:   Chief Operating Officer
AMP-18 MC LLC
By:	/s/ Dana L. Niles
	Name:   Dana L. Niles
	Title:   Chief Operating Officer